Company intelligence / Profile preview

Velico

Beverly, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

Velico’s FrontlineODP™ system received FDA Investigational Device Exemption approval in June 2021, Phase 1 escalating dose safety study started December 2022, with BARDA funding for clinical and commercial readiness; the product conducted initial clinical safety studies, aims to support rapid transfusion in pre-hospital and emergency/military settings[4][1].

Therapeutic areas: HematologyOther
Modalities: DeviceBiologicBlood product (plasma)
Industry: Biotech

Drug pipeline

3 assets

dried plasma

2 more assets in the full pipeline.

Request access →

Partnerships

American National Red Cross (blood center education program)BARDA (Biomedical Advanced Research and Development Authority, contract funding)Entegrion (past IP/license collaboration, now IP purchased back by Velico)

Beyond the preview

Go deeper on Velico.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Velico.

Explore the full profile